Antiva Biosciences, a South San Francisco, CA-based biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, raised $15m in Series C-1 financing.
The round was led by Hillhouse Capital Management, with participation from Sirona Capital and existing investors Canaan Partners, Sofinnova Ventures, Brace Pharma Capital, Osage University Partners and Lumira Capital. In conjunction with the financing, Hillhouse will appoint a representative to Antiva’s board of directors.
Founded in 2012 by Dr. Karl Hostetler of The University of California San Diego and led by Gail Maderis, president and CEO, Antiva is currently assessing the safety and efficacy of its lead compound, ABI-1968, in two Phase 1b clinical studies. One study involves intravaginal delivery of topical ABI-1968 to women with high grade cervical intraepithelial neoplasia (CIN 2,3). CIN is a precancerous condition caused by HPV in which abnormal cell growth occurs on the surface of the cervix. The second study is assessing the use of topical ABI-1968 in high grade anal intraepithelial neoplasia (AIN 2,3). There are currently no FDA-approved drugs for either of these indications.
The company intends to use the funds for additional clinical studies in both indications over the next year.